Source: Citybizlist

EnGeneIC: Daniel Von Hoff Joins Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics

SYDNEY and NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) - EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a... Read MoreThe post Daniel Von Hoff Joins Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics appeared first on citybiz.

Read full article »

EnGeneIC's Competitors | EnGeneIC's News | EnGeneIC's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

Co-CEO

Himanshu Brahmbhatt

CEO Approval Rating

68/100

EnGeneIC is an Australia-based biopharmaceutical company that develops and commercializes therapies for the treatment of cancer and infectious diseases.